Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738800 · ClinicalTrials.gov registry record · Phase 2
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
A Phase 2 study, sponsored by Mayne Pharma International Pty.
- Terminated
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT03738800 is a Phase 2 study that was terminated before completion, run by Mayne Pharma International Pty. The registered enrollment target is 65 participants.
The verdict
NCT03738800, a Phase 2 study, was terminated before completion, sponsored by Mayne Pharma International Pty.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale.
Interventions
- DRUG CD5789 Cream 200 µg/g
- DRUG CD5789 Cream 100 µg/g
- DRUG CD5789 Cream Vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-09-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03738800
The ClinicalTrials.gov registry entry for NCT03738800 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayne Pharma International Pty, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CD5789 Cream 200 µg/g is the first listed.
NCT03738800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03738800 about?
NCT03738800 is a clinical study titled "A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis". This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale.
What is the current status of trial NCT03738800?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2019-05-01. Estimated completion is 2021-09-03.
What interventions are being tested in trial NCT03738800?
The interventions under investigation include: CD5789 Cream 200 µg/g (DRUG), CD5789 Cream 100 µg/g (DRUG), CD5789 Cream Vehicle (DRUG).
Who is sponsoring clinical trial NCT03738800?
This trial is sponsored by Mayne Pharma International Pty, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.